Acadia Pharmaceuticals to Announce First Quarter 2022 Financial Results on May 4, 2022
21 April 2022 - 11:00PM
Business Wire
Company to host conference call and webcast on
Wednesday, May 4, 2022, at 4:30 p.m. Eastern Time
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that
it will report first quarter 2022 financial results on Wednesday,
May 4, 2022, after the close of the U.S. financial markets.
Acadia’s management team will also host a conference call and
webcast on May 4, 2022, at 4:30 p.m. Eastern Time to discuss
financial results and operations.
The conference call may be accessed by dialing 855-638-4820 for
participants in the United States or Canada and 443-877-4067 for
international callers (reference passcode 6989476). A telephone
replay of the conference call may be accessed through May 19, 2022
by dialing 855-859-2056 for callers in the United States or Canada
and 404-537-3406 for international callers (reference passcode
6989476). The conference call also will be webcast live on Acadia’s
website, www.acadia-pharm.com under the investors section and will
be archived there until June 1, 2022.
About Acadia Pharmaceuticals
Acadia is advancing breakthroughs in neuroscience to elevate
life. For more than 25 years we have been working at the forefront
of healthcare to bring vital solutions to people who need them
most. We developed and commercialized the first and only approved
therapy for hallucinations and delusions associated with
Parkinson’s disease psychosis. Our late-stage development efforts
are focused on treating psychosis in patients with dementia, the
negative symptoms of schizophrenia and Rett syndrome. Our
early-stage development efforts are focused on novel approaches to
pain management, cognition and neuropsychiatric symptoms in central
nervous system disorders. For more information, visit us at
www.acadia-pharm.com and follow us on LinkedIn and Twitter.
Forward-Looking Statements
Statements in this press release that are not strictly
historical in nature are forward-looking statements. These
statements include but are not limited to statements regarding the
timing of future events. These statements are only predictions
based on current information and expectations and involve a number
of risks and uncertainties. Actual events or results may differ
materially from those projected in any of such statements due to
various factors, including the risks and uncertainties inherent in
drug development, approval and commercialization. For a discussion
of these and other factors, please refer to Acadia’s annual report
on Form 10-K for the year ended December 31, 2021 as well as
Acadia’s subsequent filings with the Securities and Exchange
Commission. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof.
This caution is made under the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. All
forward-looking statements are qualified in their entirety by this
cautionary statement and Acadia undertakes no obligation to revise
or update this press release to reflect events or circumstances
after the date hereof, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220421005224/en/
Media Contact: Acadia Pharmaceuticals Inc. Deb Kazenelson (818)
395-3043 media@acadia-pharm.com
Investor Contact: Acadia Pharmaceuticals Inc. Mark Johnson, CFA
(858) 261-2771 ir@acadia-pharm.com
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Apr 2024 to May 2024
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From May 2023 to May 2024